✦ LIBER ✦

A Phase II Trial of Topotecan in Esophageal Carcinoma: A Southwest Oncology Group Study (SWOG 9339)

✍ Scribed by John S. Macdonald; Joth L. Jacobson; Steven J Ketchel; Geoffrey Weiss; Sarah Taylor; Glenn Mills; J. Phillip Kuebler; Saul Rivkin; Marcel Conrad

Book ID: 110234894
Publisher: Springer US
Year: 2000
Tongue: English
Weight: 24 KB
Volume: 18
Category: Article
ISSN: 0167-6997
DOI: 10.1023/a:1006390216220

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial to topotecan in hepatocel

Phase II trial to topotecan in hepatocellular carcinoma: A Southwest Oncology Group study

✍ James G. Wall; Jacqueline K. Benedetti; Mark A. O'Rourke; Ronald B. Natale; John 📂 Article 📅 1997 🏛 Springer US 🌐 English ⚖ 23 KB

Phase II evaluation of topotecan in pati

Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)

✍ John S. Macdonald; Jacqueline K. Benedetti; Manuel Modiano; David S. Alberts 📂 Article 📅 1997 🏛 Springer US 🌐 English ⚖ 24 KB

Phase II trial of topotecan in advanced

Phase II trial of topotecan in advanced gastric cancer: A Southwest Oncology Group study

✍ Jacqueline K. Benedetti; Howard A. Burris III; Stanley P. Balcerzak; John S. Mac 📂 Article 📅 1997 🏛 Springer US 🌐 English ⚖ 22 KB

Phase II trial of trimetrexate in advanc

Phase II trial of trimetrexate in advanced esophageal cancer: A southwest oncology group study

✍ Thomas R. Fleming; Thomas D. Brown; S. William Ross; John S. Macdonald 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 202 KB

Phase II trial of edatrexate in relapsed

Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124)

✍ Frederick J. Meyers; Danika Lew; Primo N. Lara; Steve Williamson; Ernest Marshal 📂 Article 📅 1998 🏛 Springer US 🌐 English ⚖ 48 KB

A phase II trial of estramustine and eto

A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407)

✍ Kenneth J. Pienta; Emily I. Fisher; Mario A. Eisenberger; Glenn M. Mills; J. Wen 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

BACKGROUND. The combination of oral estramustine and oral etoposide has generated response rates of 40±50% in patients with hormone refractory prostate cancer in single institution trials. This study tested this regimen in a multi-institutional setting. METHODS. Fifty-®ve patients were accrued over